scispace - formally typeset
J

Jonathan H. Sherman

Researcher at West Virginia University

Publications -  70
Citations -  3228

Jonathan H. Sherman is an academic researcher from West Virginia University. The author has contributed to research in topics: Cancer cell & Cancer. The author has an hindex of 25, co-authored 70 publications receiving 2636 citations. Previous affiliations of Jonathan H. Sherman include George Washington University Hospital & Washington University in St. Louis.

Papers
More filters
Journal ArticleDOI

Cold atmospheric plasma, a novel promising anti-cancer treatment modality.

TL;DR: This review provides a comprehensive introduction of the basics of CAP, state of the art research in this field, the primary challenges, and future directions to cancer biologists.
Journal ArticleDOI

Current trends in the surgical management and treatment of adult glioblastoma.

TL;DR: This paper highlights the common pathophysiology attributes of glioblastoma, surgical options for diagnosis/treatment, current thoughts of extent of resection of tumor, and post-operative (neo)adjuvant treatment.
Journal ArticleDOI

Principles of using Cold Atmospheric Plasma Stimulated Media for Cancer Treatment.

TL;DR: This study demonstrated several principles to optimize the anti-cancer capacity of the CAPs media on glioblastoma cells and breast cancer cells, using larger wells on a multi-well plate, smaller gaps between the plasma source and the media, and smaller media volume to obtain a stronger anti- cancers media composition.
Journal ArticleDOI

The effect of tuning cold plasma composition on glioblastoma cell viability.

TL;DR: A term “plasma dosage” is defined to summarize the relationship of all the characteristics and cell viability in the plasma jet to determine a mechanism of CAP therapy on glioblastoma cells (U87) through an understanding of the composition of the plasma.
Journal ArticleDOI

Anti-Cancer Therapies of 21st Century: Novel Approach to Treat Human Cancers Using Cold Atmospheric Plasma

TL;DR: These effects support the potential direct (CAP) and indirect (CAP-activated media) applications for adjuvant anti-cancer therapeutics, in a combination with the chemo-, radio-, and nano-therapies.